Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Use of amprenavir in preparation of medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis

A technology for acute respiratory distress and acute lung injury, which is applied in the application field of amprenavir in the preparation of drugs for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis, and can solve the problem of increasing CD4 cell count, Pharmacological effects have not been reported and other issues

Inactive Publication Date: 2014-10-08
BINZHOU MEDICAL COLLEGE
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Long-term application of amprenavir can reduce HIV viral load in blood and increase CD 4 The count of cells reduces the chance of AIDS infection, improves the quality of life, and prolongs life, but the pharmacological effects of amprenavir in the prevention or treatment of ALI / ARDS and pulmonary fibrosis have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of amprenavir in preparation of medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis
  • Use of amprenavir in preparation of medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis
  • Use of amprenavir in preparation of medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1 Preparation of Amprenavir Capsules

[0013] Weigh 120.0g amprenavir, and 120.0g carboxymethyl starch sodium, mix well and pass through a 100 mesh sieve, add an appropriate amount of 3% PVP K30 Appropriate amount of water solution to prepare soft material, granulate with 20-mesh sieve, dry at 60°C for 3 hours, granulate with 18-mesh sieve, add 2.0g magnesium stearate, pack into capsules, about 240mg per capsule, and obtain.

experiment example 2

[0025]Experimental Example 2 Effect of Amprenavir on Acute Lung Injury / Acute Respiratory Distress Syndrome (ALI / ARDS) Model Rats Induced by Cecal Ligation and Perforation

[0026] 2.1 Drugs and reagents

[0027] Amprenavir (purity 99.5%, purchased from Shanghai Hanxiang Biotechnology Co., Ltd.)

[0028] Limulus reagent kit (Fuzhou Xinbei Biochemical Industry Co., Ltd., Fujian Province, batch number: 080430)

[0029] Anti-Aquaporin5 antibody (abcam company, ab104751)

[0030] RAGE primary antibody was purchased from Sigma.

[0031] Experimental animals: SPF grade Sprague Dawley rats, male, weighing 150g-200g, provided by the Experimental Animal Center of Shandong Luye Pharmaceutical Co., Ltd., the animal qualification certificate number is: SYXK (Lu) 20030020.

[0032] 2.2 Experimental methods and results

[0033] 2.2.1 Preparation of rats with cecal ligation and puncture (CLP)

[0034] Rats were fasted in the morning on the day of operation, placed in the supine position ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a new medical use of amprenavir and specifically relates to a use of the amprenavir for inhibiting the apoptosis of type I alveolar epithelial cells, promoting the expression of the receptor for advanced glycation endproducts of the type I alveolar epithelial cells, further inhibiting the occurrence and development of the ALI / ARDS and the pulmonary fibrosis and finally preventing or treating acute lung injury / acute respiratory distress syndrome (ALI / ARDS) and pulmonary fibrosis. In the use, the dosage of the amprenavir ranges from 120mg to 6000mg, preferably from 240mg to 3000mg.

Description

technical field [0001] The present invention relates to Amprenavir suppressing the occurrence and development of acute lung injury / acute respiratory distress syndrome (ALI / ARDS) and pulmonary fibrosis so as to prevent or treat ALI / ARDS and pulmonary fibrosis; Type I alveolar epithelial cell apoptosis, promote the expression of receptor for advanced glycation endproducts (RAGE) in type I alveolar epithelial cells, so as to prevent or treat ALI / ARDS and pulmonary fibrosis. Background technique [0002] Acute lung injury / acute respiratory distress syndrome (ALI / ARDS) is a common critical illness with a high mortality rate, which seriously threatens the life of critically ill patients and affects their quality of life. ALI / ARDS is acute hypoxic respiratory function caused by diffuse pulmonary interstitial and alveolar edema caused by damage to pulmonary capillary endothelial cells and alveolar epithelial cells during non-cardiogenic diseases such as severe infection, shock, trau...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/635A61P11/00
Inventor 蒋王林赵峰纪云霞徐洋
Owner BINZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com